■Overview of operating results for the fiscal year ended March 31, 2026
Net sales for the consolidated fiscal year ended March 31, 2026 were 137,851 million yen (up 15.8% year on year). Operating income was 32,529 million yen (up 47.4% year on year), and ordinary income was 32,244 
million yen (up 49.4% year on year). Profit attributable to owners of the parent was 24,011 million yen (up 
122.7% year on year), which reflects a gain on liquidation of subsidiaries and associates recorded as extraordinary income and corporate action expenses recorded as extraordinary losses.

 

Results by segment were as follows.
The Group consists of segments based on operating subsidiaries and comprises two reportable segments: the Electronics business and the Medical and Pharmaceuticals business.

 

■Electronics
Due to increased sales volumes of PKG and rigid products, net sales in the Electronics business  totaled 95,285 million yen (up 16.6% year on year), an increase of 13,582 million yen from the previous fiscal year. Operating income was 29,177 million yen (up 36.0%), an increase of 7,718 million yen year on year.
During the period under review, the average exchange rate was 150.9 JPY per USD, representing a appreciation of 1.6 yen compared to the previous period’s average rate of 152.5 JPY per USD.

Electronics

＜Reasons for the Increase in Net Sales＞
 

  • PKG products
    • Sales volume increased, particularly for memory products, due to the recovery in demand.
    • Supported by strong demand stemming from the growing use of AI, sales 
      volume increased, mainly for dry film products for memory applications.
  • Rigid products
    • Sales volume increased, mainly for Automotive-related products and smartphone products in China
    • Fluctuations in demand for certain end products led to a decrease in demand for 
      our product, and sales volume of display (white dry film) products decreased.
  • The depreciation of the yen had a negative impact on our performance

■Medical and Pharmaceuticals
Due to higher contract volumes in the contract manufacturing business and  increased demand for certain products in the manufacturing and marketing business, net sales in the Medical and Pharmaceuticals business totaled 36,490 million yen (up 15.6% year on year), an increase of 4,932 million yen from the previous fiscal year. Operating income was 5,063 million yen (up 147.1%), an increase of 3,014 million yen year on year.

Medical and Pharmaceuticals

＜Reasons for the Increase in Net Sales＞
 

  • Taiyo Pharma Tech Co., Ltd. (CDMO)
    • Contract volume from exiting customers increased.
    • The start of full-scale contract manufacturing for new customers resulted
      in an increase in contract volume.
  •  Taiyo Pharma Co., Ltd. (manufacturing and marketing of pharmaceuticals)
    • Sales volume decreased for items subject to the elective care scheme, 
      which was implemented from October 2024.
    • Sale volume increased due to higher demand in line with supply
      shortages of drugs with the same indications at other companies.
    • Sales increased due to the upward revision of drug prices for certain 
      products following the NHI drug price revision.

(Unit: millions of yen)

Item

FY2025

FY2026

Change

%  of  Changes

Net Sales

  119,010

137,851

18,841

 16%

Operating Income

  22,067

32,529

10,462

 47%

Ordinary Income

  21,577

32,244

10,667

 49%

Profit attributable to owners of parent

  10,780

24,011

13,231

 123%